The primary objective for this study is to evaluate the safety of E2007 given as adjunctive long-term treatment in patients with refractory partial onset seizures with or without secondary generalization that completed the E2007-A001-206 or the E2007-G000-208 study
Data and Resources
- A 14-Month Open-Label Extension Phase of the Double-Blind Placebo-Controlled Dose-Escalation Parallel-Group Study of E2007 as an Adjunctive Therapy in Patients With Refractory Partial Seizures revised per Amendments 02 and 03json
The primary objective for this study is to evaluate the safety of E2007...
|Release Date|| |
License Not Specified
|Public Access Level|| |